Abstract
Management of psoriasis has undergone a revolution with the introduction of biologics and novel small-molecule drugs. Still, a considerable proportion of patients are not well treated due to, e.g., lack of accessibility, high pricing, or contraindications to available therapies. Oral roflumilast, a phosphodiesterase (PDE)-4 inhibitor approved for chronic obstructive pulmonary disease, has been proposed as an affordable, effective, and safe off-label therapy in psoriasis [2]. Yet, real-world evidence is warranted. The aim of this study was to assess effectiveness and drug survival of oral roflumilast in patients with plaque-type psoriasis.
| Originalsprog | Engelsk |
|---|---|
| Tidsskrift | American Journal of Clinical Dermatology |
| ISSN | 1175-0561 |
| DOI | |
| Status | Accepteret/In press - 2024 |
Bibliografisk note
Funding Information:Mette Gyldenl\u00F8ve: Outside the submitted work: Speaker honoraria from Galderma Nordic AB. Christoffer Nissen: Outside the submitted work: Served on advisory boards for UCB, LEO Pharma, and AbbVie. Sascha Stave None. Simon Francis Thomsen: Outside the submitted work: Speaker or served on advisory boards for AbbVie, Almirall, Eli Lilly, Galderma, Incyte, Janssen Pharmaceuticals, LEO Pharma, Novartis, Pfizer, Sanofi, UCB Pharma, and Union Therapeutics, and has received research support from AbbVie, Janssen Pharmaceuticals LEO Pharma, Novartis, Sanofi, and UCB Pharma. Alexander Egeberg: Outside the submitted work: Research funding from the Danish Psoriasis Foundation, the Kgl. Hofbuntmager Aage Bang Foundation, the Simon Spies Foundation, Pfizer, Eli Lilly, Novartis, AbbVie, and Janssen Pharmaceuticals. Consultant and/or speaker honoraria from AbbVie, Almirall, Bristol-Myers Squibb, Dermavant, Eli Lilly and Company, Galderma, Gal\u00E1pagos NV, Horizon Therapeutics, Janssen Pharmaceuticals, LEO Pharma, Mylan, Novartis, Pfizer, Samsung Bioepis Co., Ltd., UCB, and Union Therapeutics. Currently employed by LEO Pharma. Nikolai Loft: Outside the submitted work: Paid speaker for Eli Lilly, Janssen Cilag, and Sandoz.